BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Cappella Medical Devices Ltd to Share Data Documenting Benefits of Full Ostial Protection at EuroPCR 2011


5/17/2011 9:20:44 AM

PARIS--(BUSINESS WIRE)--Cappella, Inc. (Cappella), a medical device company developing dynamic solutions for the treatment of coronary bifurcation disease, today revealed how its innovative Sideguard® coronary sidebranch technology will be featured in several scientific sessions at this week’s EuroPCR Congress in Paris, including a new European survey on the challenges in treating bifurcation disease. Developed to protect the ostium of the sidebranch, the Cappella Sideguard coronary sidebranch technology offers interventional cardiologists a dynamic, effective, and easy-to-use solution in the treatment of bifurcation disease. This next generation stent platform preserves the sidebranch of diseased coronary arteries by protecting the ostium and minimising plaque shift. Cappella is currently engaged in a large-scale registry of more than 250 patients in Europe which should further confirm the ease of use and the reduced TVF rate.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->